Phenytoin
Traumatic Brain Injury
Floatz Rating
B63/100
Confidence
Indicative
Sponsor
All India Institute of Medical Sciences, Jodhpur
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07072624CT.gov Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial) | — | Recruiting | — | — | — |
NCT04573803CT.gov Pharmacological Management of Seizures Post Traumatic Brain Injury | — | Not Yet Recruiting | — | — | — |
NCT00618436CT.gov Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention | — | Completed | — | — | — |
NCT00598923CT.gov Preventing Epilepsy After Traumatic Brain Injury With Topiramate | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Traumatic Brain Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Phenytoin (this asset) | All India Institute of Medical Sciences, Jodhpur | Approved | B · 63 |
| Melatonin | Children's National Research Institute | P4 | BBB |
| Valproic Acid | Northwestern University | P4 | BBB |
| Apsolol | Tanta University | P4 | BBB |
| Nepenthe | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Dexmedetomidine | Universitas Jenderal Soedirman | P4 | BB |
| Amantadine | SHINKEI Therapeutics, Inc | P4 | BB |
| Serostim | Anhui Provincial Hospital | P4 | BB |
| Dextromethorphan | Avanir Pharmaceuticals | P4 | BB |
+42 more in the Traumatic Brain Injury cohort
Other indications for Phenytoin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Epilepsy | — | P4 | BB · 66 |
| Epilepsy With Generalized Tonic-Clonic Seizures | — | P4 | B · 61 |
| Subarachnoid Hemorrhage | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Phenytoin in Traumatic Brain Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/phenytoin-traumatic-brain-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →